Tivorsan Pharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Out of Business
Tivorsan Pharmaceuticals General Information
Description
Developer of novel therapeutic drugs designed to treat orphan neuromuscular diseases and disorders. The company's drugs are designed to treat serious neuromuscular disorders, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) as well as other progressive life-threatening neuromuscular disorders, enabling doctors to treat patients suffering from neuromuscular diseases and disorders.
Contact Information
Website
www.tivorsan.comCorporate Office
- 3 Davol Square
- A340
- Providence, RI 02903
- United States
Corporate Office
- 3 Davol Square
- A340
- Providence, RI 02903
- United States
Tivorsan Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Out of Business | 01-May-2021 | Completed | Out of Business | |||
| 8. Secondary Transaction - Private | 01-Nov-2020 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 25-Oct-2018 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series D) | 17-Mar-2017 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 01-Jan-2015 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 05-Jun-2013 | Completed | Generating Revenue | |||
| 3. Grant | 21-Feb-2012 | Completed | Generating Revenue | |||
| 2. Grant | 05-Jan-2012 | $1M | $1.12M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 23-Feb-2011 | $1.12M | $1.12M | Completed | Generating Revenue |
Tivorsan Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 3,759,400 | $0.010000 | $0.09 | $1.33 | $1.33 | 1x | $1.33 | 8.92% |
| Series A | 3,472,223 | $0.010000 | $0.05 | $0.72 | $0.72 | 1x | $0.72 | 8.24% |
Tivorsan Pharmaceuticals Patents
Tivorsan Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2013329296-A1 | Biglycan variant polypeptides and methods of use | Active | 10-Oct-2012 | ||
| AU-2013329296-A9 | Biglycan variant polypeptides and methods of use | Active | 10-Oct-2012 | ||
| AU-2013329296-B2 | Biglycan variant polypeptides and methods of use | Inactive | 10-Oct-2012 | ||
| CA-2887303-A1 | Biglycan variant polypeptides and methods of use | Inactive | 10-Oct-2012 | ||
| EP-2906292-A1 | Biglycan variant polypeptides and methods of use | Inactive | 10-Oct-2012 | C07K14/4725 |
Tivorsan Pharmaceuticals Signals
Tivorsan Pharmaceuticals FAQs
-
When was Tivorsan Pharmaceuticals founded?
Tivorsan Pharmaceuticals was founded in 2007.
-
Where is Tivorsan Pharmaceuticals headquartered?
Tivorsan Pharmaceuticals is headquartered in Providence, RI.
-
What is the size of Tivorsan Pharmaceuticals?
Tivorsan Pharmaceuticals has 6 total employees.
-
What industry is Tivorsan Pharmaceuticals in?
Tivorsan Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Tivorsan Pharmaceuticals a private or public company?
Tivorsan Pharmaceuticals is a Private company.
-
What is Tivorsan Pharmaceuticals’s current revenue?
The current revenue for Tivorsan Pharmaceuticals is .
-
How much funding has Tivorsan Pharmaceuticals raised over time?
Tivorsan Pharmaceuticals has raised $13.8M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process